Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A FIXED-SEQUENCE CROSSOVER, DRUG-DRUG INTERACTION STUDY EVALUATING THE EFFECT OF THE CYTOCHROME P450 3A INHIBITOR ITRACONAZOLE ON DNL151 IN HEALTHY SUBJECTS

Trial Profile

A FIXED-SEQUENCE CROSSOVER, DRUG-DRUG INTERACTION STUDY EVALUATING THE EFFECT OF THE CYTOCHROME P450 3A INHIBITOR ITRACONAZOLE ON DNL151 IN HEALTHY SUBJECTS

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2018

At a glance

  • Drugs DNL-151 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Denali Therapeutics Inc
  • Most Recent Events

    • 26 Dec 2017 New trial record
    • 20 Dec 2017 According to a Denali Therapeutics media release, the company has commenced dosing in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top